{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:23:39Z","timestamp":1792268619693,"version":"4.4.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004737","name":"National Health Research Institutes","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004737","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.lfs.2021.119574","type":"journal-article","created":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T02:18:23Z","timestamp":1620181103000},"page":"119574","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["DBPR108, a novel dipeptidyl peptidase-4 inhibitor with antihyperglycemic activity"],"prefix":"10.1016","volume":"278","author":[{"given":"Kai-Chia","family":"Yeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teng-Kuang","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Yu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Bo","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Hsien","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Wen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-Hui","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsuan-Hui","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jen-Shin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsu","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weir-Torn","family":"Jiaang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Sheng","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiung-Tong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2021.119574_bb0005","doi-asserted-by":"crossref","first-page":"107843","DOI":"10.1016\/j.diabres.2019.107843","article-title":"Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9(th) edition","volume":"157","author":"Saeedi","year":"2019","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.lfs.2021.119574_bb0010","series-title":"Global Report on Diabetes","author":"World Health Organization","year":"2016"},{"issue":"4","key":"10.1016\/j.lfs.2021.119574_bb0015","doi-asserted-by":"crossref","first-page":"753","DOI":"10.2147\/VHRM.S1707","article-title":"Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes","volume":"4","author":"Richter","year":"2008","journal-title":"Vasc. Health Risk Manag."},{"issue":"3","key":"10.1016\/j.lfs.2021.119574_bb0020","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1210\/edrv-16-3-390","article-title":"Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide","volume":"16","author":"Fehmann","year":"1995","journal-title":"Endocr. Rev."},{"issue":"2","key":"10.1016\/j.lfs.2021.119574_bb0025","first-page":"60","article-title":"Incretins: a new treatment option for type 2 diabetes?","volume":"65","author":"Geelhoed-Duijvestijn","year":"2007","journal-title":"Neth. J. Med."},{"issue":"8","key":"10.1016\/j.lfs.2021.119574_bb0030","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.2337\/diabetes.50.8.1720","article-title":"Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor","volume":"50","author":"Burcelin","year":"2001","journal-title":"Diabetes"},{"issue":"8","key":"10.1016\/j.lfs.2021.119574_bb0035","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/(SICI)1521-1878(199808)20:8<642::AID-BIES7>3.0.CO;2-K","article-title":"Glucagon-like peptide-1 (GLP-1): a gut hormone of potential interest in the treatment of diabetes","volume":"20","author":"Ahr\u00e9n","year":"1998","journal-title":"Bioessays"},{"issue":"6","key":"10.1016\/j.lfs.2021.119574_bb0040","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1210\/jc.2003-031403","article-title":"Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men","volume":"89","author":"Gutzwiller","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"9","key":"10.1016\/j.lfs.2021.119574_bb0045","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.peptides.2005.02.016","article-title":"Energy expenditure by intravenous administration of glucagon-like peptide-1 mediated by the lower brainstem and sympathoadrenal system","volume":"26","author":"Osaka","year":"2005","journal-title":"Peptides"},{"issue":"10","key":"10.1016\/j.lfs.2021.119574_bb0050","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.2337\/diacare.26.10.2929","article-title":"Enhancing incretin action for the treatment of type 2 diabetes","volume":"26","author":"Drucker","year":"2003","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.lfs.2021.119574_bb0055","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1210\/me.2002-0306","article-title":"Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis","volume":"17","author":"Drucker","year":"2003","journal-title":"Mol. Endocrinol."},{"issue":"3","key":"10.1016\/j.lfs.2021.119574_bb0060","doi-asserted-by":"crossref","first-page":"609","DOI":"10.2337\/diabetes.50.3.609","article-title":"Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients","volume":"50","author":"Vilsb\u00f8ll","year":"2001","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.lfs.2021.119574_bb0065","doi-asserted-by":"crossref","first-page":"658","DOI":"10.2337\/diab.42.5.658","article-title":"Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable","volume":"42","author":"Orskov","year":"1993","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.lfs.2021.119574_bb0070","doi-asserted-by":"crossref","first-page":"413","DOI":"10.4103\/2230-8210.111625","article-title":"Glucagon-like peptide-1 analogues: an overview","volume":"17","author":"Gupta","year":"2013","journal-title":"Indian J. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.lfs.2021.119574_bb0075","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1517\/13543784.17.6.845","article-title":"Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes","volume":"17","author":"Mikhail","year":"2008","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"1","key":"10.1016\/j.lfs.2021.119574_bb0080","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0167-0115(99)00089-0","article-title":"Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides","volume":"85","author":"Mentlein","year":"1999","journal-title":"Regul. Pept."},{"issue":"386","key":"10.1016\/j.lfs.2021.119574_bb0085","article-title":"DPP4 in diabetes","volume":"6","author":"R\u00f6hrborn","year":"2015","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.lfs.2021.119574_bb0090","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1592\/phco.30.5.463","article-title":"Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus","volume":"30","author":"Neumiller","year":"2010","journal-title":"Pharmacotherapy"},{"issue":"12","key":"10.1016\/j.lfs.2021.119574_bb0095","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1016\/j.bmcl.2010.04.124","article-title":"(2S,4S)-1-[2-(1,1-dimethyl-3-oxo-3-pyrrolidin-1-yl-propylamino)acetyl]-4-fluoro-pyrrolidine-2-carbonitrile: a potent, selective, and orally bioavailable dipeptide-derived inhibitor of dipeptidyl peptidase IV","volume":"20","author":"Yeh","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"4","key":"10.1016\/j.lfs.2021.119574_bb0100","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1254\/jjp.88.442","article-title":"Dipeptidyl peptidase IV inhibition improves impaired glucose tolerance in high-fat diet-fed rats: study using a Fischer 344 rat substrain deficient in its enzyme activity","volume":"88","author":"Mitani","year":"2002","journal-title":"Jpn. J. Pharmacol."},{"issue":"9","key":"10.1016\/j.lfs.2021.119574_bb0105","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1007\/s00125-007-0737-6","article-title":"Continuous stimulation of human glucagon-like peptide-1 (7-36) amide in a mouse model (NOD) delays onset of autoimmune type 1 diabetes","volume":"50","author":"Zhang","year":"2007","journal-title":"Diabetologia"},{"issue":"2","key":"10.1016\/j.lfs.2021.119574_bb0110","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.bbrc.2008.10.059","article-title":"Islet alpha cell number is maintained in microencapsulated islet transplantation","volume":"377","author":"Bohman","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"5","key":"10.1016\/j.lfs.2021.119574_bb0115","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.bmcl.2006.12.019","article-title":"3-[2-((2S)-2-cyano-pyrrolidin-1-yl)-2-oxo-ethylamino]-3-methyl-butyramide analogues as selective DPP-IV inhibitors for the treatment of type-II diabetes","volume":"17","author":"Coumar","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"5","key":"10.1016\/j.lfs.2021.119574_bb0120","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.2337\/diacare.28.5.1092","article-title":"Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes","volume":"28","author":"DeFronzo","year":"2005","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.lfs.2021.119574_bb0125","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.2337\/diacare.27.11.2628","article-title":"Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes","volume":"27","author":"Buse","year":"2004","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.lfs.2021.119574_bb0130","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2337\/diacare.28.5.1083","article-title":"Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea","volume":"28","author":"Kendall","year":"2005","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.lfs.2021.119574_bb0135","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.beem.2007.09.003","article-title":"Incretin hormone mimetics and analogues in diabetes therapeutics","volume":"21","author":"Green","year":"2007","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.lfs.2021.119574_bb0140","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1089\/dia.2019.0185","article-title":"Oral semaglutide: a review of the first oral glucagon-like peptide 1 receptor agonist","volume":"22","author":"Bucheit","year":"2020","journal-title":"Diabetes Technol. Ther."},{"issue":"12","key":"10.1016\/j.lfs.2021.119574_bb0145","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.1016\/j.bmcl.2007.03.098","article-title":"Triazolopiperazine-amides as dipeptidyl peptidase IV inhibitors: close analogs of JANUVIA (sitagliptin phosphate)","volume":"17","author":"Kim","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"13","key":"10.1016\/j.lfs.2021.119574_bb0150","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1021\/jm030091l","article-title":"1-[[(3-Hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties","volume":"46","author":"Villhauer","year":"2003","journal-title":"J. Med. Chem."},{"issue":"17","key":"10.1016\/j.lfs.2021.119574_bb0155","first-page":"1513","article-title":"FDA approves saxagliptin for type 2 diabetes","volume":"66","author":"Traynor","year":"2009","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.lfs.2021.119574_bb0160","doi-asserted-by":"crossref","first-page":"k872","DOI":"10.1136\/bmj.k872","article-title":"Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study","volume":"360","author":"Abrahami","year":"2018","journal-title":"Bmj"},{"issue":"5","key":"10.1016\/j.lfs.2021.119574_bb0165","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.anai.2011.02.012","article-title":"DPP-4 inhibitors and angioedema: a cause for concern?","volume":"106","author":"Byrd","year":"2011","journal-title":"Ann. Allergy Asthma Immunol."},{"issue":"10","key":"10.1016\/j.lfs.2021.119574_bb0170","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1002\/pds.3503","article-title":"Association of musculoskeletal complaints and gliptin use: review of spontaneous reports","volume":"22","author":"Tarapu\u00e9s","year":"2013","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.lfs.2021.119574_bb0175","doi-asserted-by":"crossref","first-page":"12348","DOI":"10.1038\/srep12348","article-title":"Inhibition of dipeptidyl peptidase 8\/9 impairs preadipocyte differentiation","volume":"5","author":"Han","year":"2015","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/j.lfs.2021.119574_bb0180","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.2337\/diabetes.54.10.2988","article-title":"Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9","volume":"54","author":"Lankas","year":"2005","journal-title":"Diabetes."},{"issue":"2","key":"10.1016\/j.lfs.2021.119574_bb0185","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.bcp.2009.03.032","article-title":"Biochemistry, pharmacokinetics, and toxicology of a potent and selective DPP8\/9 inhibitor","volume":"78","author":"Wu","year":"2009","journal-title":"Biochem. Pharmacol."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320521005609?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320521005609?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T13:37:35Z","timestamp":1731591455000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320521005609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":37,"alternative-id":["S0024320521005609"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2021.119574","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"DBPR108, a novel dipeptidyl peptidase-4 inhibitor with antihyperglycemic activity","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2021.119574","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"119574"}}